New Injection's effect on statin metabolism under the microscope

NCT ID NCT07692685

Completed Knowledge-focused Sponsor: Neurodawn Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates whether a new injectable drug called Y-3 changes how the body processes rosuvastatin, a widely used cholesterol-lowering medication. Twenty healthy adults aged 18 to 50 will take rosuvastatin alone and then together with Y-3 to measure any drug-drug interaction. The goal is to ensure safe and effective use of Y-3 if it is later prescribed alongside statins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Y-3 for injection and rosuvastatin calcium tablets
What this could lead to: If successful, this study could help doctors understand whether Y-3 can be safely used alongside rosuvastatin, informing safer prescribing.
What could go wrong: This is a small, early-phase study in healthy volunteers, not patients. Results may not predict real-world effects or guarantee safety in broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-DRUG INTERACTION HEALTHY MALE AND FEMALE SUBJECTS PHASE 1 PHARMACODYNAMIC STUDY ROSUVASTATIN CALCIUM TABLET

Contacts and locations

Show contact details

Locations

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.